Dual-action nanotherapy: Temozolomide-loaded, anti-PD-L1 scFv-functionalized lipid nanocarriers for targeted glioblastoma therapy.

ABSTRACT: Glioblastoma (GBM) is a highly malignant brain tumor with limited treatment options and poor prognosis. GBM exhibits resistance to conventional therapies, including temozolomide (TMZ), radiotherapy, and immunotherapy, partly due to immunosuppressive mechanisms such as programmed death-ligand 1 (PD-L1) overexpression. To address these challenges, we developed TMZ-loaded nanostructured lipid carriers (NLCs) conjugated with anti-PD-L1 single-chain variable fragments (scFv) for dual chemo-immunotherapy. The anti-PD-L1 scFv enabled active targeting of PD-L1-expressing tumor cells while mitigating immune evasion, and the NLCs efficiently crossed the blood-brain barrier (BBB), delivering TMZ to the tumor site. In vitro studies confirmed nanoparticle internalization by GL261 glioma cells and speci

SUBMITTER: Aytekin E 

PROVIDER: S-EPMC12449728 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature